Short answer
RET MEN2 genetic testing looks for inherited gain-of-function variants in RET when multiple endocrine neoplasia type 2 is suspected. MEN2 is most closely linked with medullary thyroid carcinoma, and depending on the subtype and variant, pheochromocytoma and parathyroid disease may also be part of surveillance planning.
When testing is considered
| Situation | Testing question | Why it matters |
|---|---|---|
| Medullary thyroid cancer | Is germline RET testing needed? | A hereditary result can affect relatives and timing of care. |
| Known family RET variant | Should relatives have targeted testing? | Targeted testing can identify who needs MEN2 surveillance. |
| MEN2B-like features | Is urgent specialist genetics and endocrine care needed? | Some RET variants carry high early-life risk. |
| Unusual pheochromocytoma or MEN2A pattern | Does the phenotype point to a specific RET workup? | The endocrine pattern can shape which test is ordered first. |
How germline and tumor testing differ
Germline RET testing answers whether the variant is inherited and potentially relevant to relatives. Tumor testing answers whether the tumor itself carries a RET change. Those are related but not interchangeable questions. A tumor-only RET result should not automatically be treated as a hereditary result without germline confirmation.
What the result can change
A pathogenic RET result can affect thyroid surgery timing, calcitonin and thyroid surveillance, pheochromocytoma screening, parathyroid monitoring, and family testing. NCI and GeneReviews both emphasize that the result matters because it can change prevention and surveillance, not just labels.
Why family testing matters
If the familial RET variant is known, targeted testing is the cleanest way to sort relatives into those who need MEN2 surveillance and those who do not. That is the practical bridge between a lab result and a family plan.
Questions to ask
- Was the result germline, tumor-only, or a raw consumer result?
- Which RET variant was found, and what is the exact protein change?
- Should relatives have targeted cascade testing?
- What thyroid, adrenal, and parathyroid follow-up is recommended?
FAQ
When is RET MEN2 testing usually considered?
It is usually considered when medullary thyroid cancer, pheochromocytoma, a known family RET variant, or a MEN2-like pattern makes inherited RET risk plausible.
Does RET testing only matter for thyroid cancer?
No. MEN2-related RET variants can also affect adrenal pheochromocytoma and parathyroid surveillance, which is why the result can change more than one part of care.
Why does germline testing matter more than tumor-only testing?
Germline testing tells you whether the change is inherited and relevant to relatives, while tumor-only testing may only reflect the cancer itself.
What does a positive RET result change?
It can change thyroid surgery timing, calcitonin and thyroid surveillance, adrenal screening, parathyroid monitoring, and family testing plans.
What does a negative RET result mean?
A negative result lowers the chance of a known RET cause, but the meaning depends on whether the correct person and correct variant were tested.
Why does family testing matter?
If a familial RET variant is known, targeted testing can identify relatives who need MEN2 surveillance and those who do not.
Related guides: MEN2A vs MEN2B genetic testing, RET negative family variant testing interpretation, RET codon 609, 611, 618, and 620 questions, and positive RET test next steps.